Brind.

The FDA granted conditional IDE approval for TransMedics utilizing the OCS Heart System.

3 reports, 2 independent Updated Aug 4
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The FDA granted conditional IDE approval for TransMedics utilizing the OCS Heart System.

Who's involved

What this event is mainly about
OCSTransmedicsFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA granted conditional IDE approval for TransMedics' OCS Heart System.1 source
  2. FDA granted conditional IDE approval for TransMedics' OCS lung system.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • PR NewswireTransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial ANDOVER, Mass., Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical techno
  • GuruFocus.comTransMedics Group Inc (TMDX) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full ear
  • Unknown outlet